NCT05540002View on ClinicalTrials.gov

Efficacy of the Quell Wearable Device for Chronic Overlapping Pain Conditions

NACompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

October 14, 2022

Primary Completion Date

September 19, 2024

Study Completion Date

September 19, 2024

Conditions
Chronic PainAdults 21 and OlderMultiple Chronic Overlapping Pain ConditionsHypersensitivity
Interventions
DEVICE

High Intensity Quell

Participants will receive 1 hour of continuous stimulation during each therapy session. Subjects are asked to complete a minimum of 3 sessions per day.

DEVICE

Low Intensity Quell

Participants will receive only three 2-minute periods of stimulation (at 0, 28, 58 minutes) during each 60-minute therapeutic session. Subjects are asked to complete a minimum of 3 sessions per day.

Trial Locations (1)

02467

Brigham and Women's Hospital Pain Management Center, Chestnut Hill

Sponsors

Collaborators (1)

NeuroMetrix, Inc.
All Listed Sponsors
collaborator

NeuroMetrix, Inc.

INDUSTRY

lead

Brigham and Women's Hospital

OTHER

NCT05540002 - Efficacy of the Quell Wearable Device for Chronic Overlapping Pain Conditions | Biotech Hunter | Biotech Hunter